Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 19, 2024, titled "Stock Exchange intimation on completion of USFDA inspection attransdermal manufacturing site".
Press Release Jul 19 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the completion of a USFDA inspection at its transdermal manufacturing site in Ahmedabad. The inspection took place over several days and concluded with two observations from the USFDA. The company expressed confidence in addressing the issues raised within the required timeline.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jul 17 2024
- Press Release (Revised) Jul 10 2024
- Press Release Jul 10 2024
- Press Release Jul 04 2024
- Press Release Jun 28 2024
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jul 22 2024
- Press Release Jul 23 2024
- Press Release Jul 31 2024
- Press Release Aug 09 2024
- Press Release Aug 23 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences